Physicochemical and structural characterization of iron-sucrose formulations: A comparative study

Pharmaceutical Development and Technology

Volumn 19, Issue 5, 2014, Pages 513-520

  Barot, Bhavesh S ^a   Parejiya, Punit B ^a   Mehta, Dharmik M ^a   Shelat, Pragna K ^a   Shah, Gaurang B ^a  

^a K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Fourier transform infrared spectroscopy; Gel permeation chromatography; Iron sucrose; Mass spectroscopy; Nuclear magnetic resonance spectroscopy; Venofer

Indexed keywords

IRON SACCHARATE; IS CLARIS; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BIOEQUIVALENCE; CARBON NUCLEAR MAGNETIC RESONANCE; COMPARATIVE STUDY; DRUG FORMULATION; GEL PERMEATION CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; THERMOGRAVIMETRY; X RAY DIFFRACTION;

ANEMIA, IRON-DEFICIENCY; CHROMATOGRAPHY, GEL; FERRIC COMPOUNDS; GLUCARIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUCROSE;

EID: 84898466052     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.795171     Document Type: Article

References (25)

1. Akarsu S, Taskin E, Yilmaz E, et al. Treatment of iron deficiency anemia with intravenous iron preparations. Acta Haematol 2006; 116:51-57.
2. Slack HG, Wilkinson JF. Intravenous treatment of anaemia with an iron-sucrose preparation. Lancet 1949;1:11-14.
3. Cancado RD, Munoz M. Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter 2011;33:461-469.
4. Sengolge G, Horl WH, Sunder-Plassmann G. Intravenous iron therapy: well-tolerated, yet not harmless. Eur J Clin Invest 2005;35: 46-51.
5. Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 2009;59:176-190.
6. Kudasheva DS, Lai J, Ulman A, Cowman MK. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem 2004;98:1757-1769.
7. Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011;78:480-491.
8. Johnson CA, Mason NA, Bailie GR. Intravenous iron products. ANNA J 1999;26:522-524.
9. Balakrishnan VS, Rao M, Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 2009;39:489-496.
10. Helenek MJ, Lange RA, Lawrence RP. Bioequivalence test for ironcontaining formulations, US Patent 7,169,359; 2007.
11. Meier T, Schropp P, Pater C, et al. Physicochemical and toxicological characterization of a new generic iron sucrose preparation. Arzneimittelforschung 2011;61:112-119.
12. Christopher CB, Rangisetty JB. Iron sucrose complexes and method of manufacture thereof, US Patent 7,674,780; 2010.
13. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15:S93-S98.
14. Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between the original iron sucrose complex venofer and the iron sucrose similar generis, and potential implications. Port J Nephrol Hypert 2009;23: 53-63.
15. Langford JI, Wilson AJC. Scherrer after sixty years: a survey and some new results in the determination of crystallite size. J Appl Crystallogr 1978;11:102-113.
16. Iron sucrose injection monograph, United States Pharmacopeia 29-National Formulary 24, USP Convention, Rockville; 2006:1179.
17. Shah R, Yang Y, Khan M, Faustino P. Molecular weight determination for colloidal iron by Taguchi optimized validated gel permeation chromatography. Int J Pharm 2008;353:21-27.
18. Kim BH, Shin K, Kwon SG, et al. Sizing by weighing: characterizing sizes of ultrasmall-sized iron oxide nanocrystals using MALDI-TOF mass spectrometry. J Am Chem Soc 2013;135: 2407-2410.
19. Gutiérrez L, del Puerto Morales M, José Lázaro F. Magnetostructural study of iron sucrose. J Magn Magn Mater 2005;293:69-74.
20. Koralewski M, Pochylski M, Gierszewski J. Magnetic birefringence of iron oxyhydroxide nanoparticles stabilised by sucrose. J Magn Magn Mater 2011;323:1140-1144.
21. Farkas E, Enyedy EA, Zekany L, Deak G. Interaction between iron(ii) and hydroxamic acids: oxidation of iron(ii) to iron(iii) by desferrioxamine b under anaerobic conditions. J Inorg Biochem 2001;83:107-114.
22. Scheinost AC, Schwertmann U. Color identification of iron oxides and hydroxysulfates. Soil Sci Soc Am J 1999;63:1463-1471.
23. Scheinost AC, Chavernas A, Barron V, Torrent J. Use and limitations of second-derivative diffuse reflectance spectroscopy in the visible to near-infrared range to identify and quantity Fe oxide minerals in soils. Clays Clay Miner 1998;46:528-536.
24. te Booy MP, de Ruiter RA, de Meere AL. Evaluation of the physical stability of freeze-dried sucrose-containing formulations by differential scanning calorimetry. Pharm Res 1992;9: 109-114.
25. Siverstein RM, Webster FX, Kiemle DJ. Spectrometric identification of organic compounds. 7th ed. New York: John Wiley and Sons; 2005.